Experts of the HARMONY Alliance will be presenting at EMN2023. We are also honored to organize a joint session EMN. Please find below more information. Would you like to meet us at EMN2023? Please send an email to communications@harmony-alliance.eu to set up an appointment.
Day/time: Saturday, 22 April, from 10.05 till 11.05 hrs.
Theme: Big Data innovations in Multiple Myeloma: New analytic tools and new insights
Speakers
EMN-HARMONY Joint Session Program (Session XI)
Multiple myeloma is a rare and highly heterogeneous hematologic malignancy, and the clinical research certainly plays a fundamental role in the management of patients with this disease. To deal with such a complex scenario, in 2005, a group of European hematologists pulled together to increase their understanding of multiple myeloma and to produce effective research projects and clinical trials. These efforts resulted in the creation of the European Myeloma Network (EMN), a non profit organization.
EMN is a highly valued HARMONY Partner. An important Multiple Myeloma project is being coordinated by the EMN within HARMONY, and it involves many European sites.
Read here the latest HARMONY Alliance press release about the Multiple Myeloma Research Result : Proposed revision of staging system for Multiple Myeloma by Mattia D'Agostino >
Click here to view the HARMONY Research Projects, including the MM projects >
#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. HARMONY is a partnership with more than 140 organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies, and medical network and associations such as ELN. Together, they have developed the HARMONY Big Data Platform and the HARMONY Datalake, which contains anonymized data records from tens of thousands of blood cancer patients. This unique research infrastructure, with advanced big data analytic and AI tools, is being used to accelerate the development of more effective treatments for patients with hematologic malignancies (blood cancers).
HARMONY has identified more than 156,000 patient datasets and has transferred more than 73,000 datasets into the HARMONY Big Data Platform. Careful procedures have been installed to ensure the anonymization and quality of the data. In addition, HARMONY data scientists have developed sophisticated methods for data harmonization and analysis. Dedicated Research Project teams are currently using the Big Data Platform to answer critical research questions that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
